IPOGrid
0002079109
IPO filing research
Veraxa Biotech Holding AG
Pharmaceutical Preparations · VRXA
follow-on
trading
priced
Nasdaq Global Market
424B5
Veraxa Biotech Holding AG IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: 424B5 on 2026-08-10. Current deal snapshot: exchange Nasdaq Global Market.
Filing Timeline
SEC EDGAR
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows F-4/A and confirms the priced prospectus.
139,732,124 shares
SPAC Class A Ordinary Share · Exchange Nasdaq Global Market · Ticker VRXA · Over-allotment 3,300,000 · Units · Public Warrants to purchase Ordinary Shares at $11.50 per share; Private Warrants to purchase Ordinary Shares at $11.50 per share · Use of proceeds Proceeds from warrant exercises, if any, to be used for general corporate purposes · Flags units, warrants
2026-08-10 · 0001829126-26-008548
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows F-4 and confirms the priced prospectus.
25,000,000 shares
Ordinary · Exchange Nasdaq Global Market · Ticker VRXA · Over-allotment 3,300,000 · Selling stockholders only · Use of proceeds Proceeds will go to the selling shareholder, Lincoln Park Capital Fund, LLC · Flags foreign_private_issuer · Underwriters Lincoln Park Capital Fund, LLC
2026-08-10 · 0001829126-26-008547
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
First tracked pre-IPO filing for this issuer.
2026-08-06 · 9999999995-26-002591
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
First tracked pre-IPO filing for this issuer.
2026-08-06 · 9999999995-26-002577
F-1/A
amended
Amended foreign registration statement
Updated foreign registration statement filed after SEC comments or deal changes.
Updates the prior F-4 filing.
Ordinary Shares · Warrants exercisable at $11.50 per share · Use of proceeds Proceeds used for business combination and general corporate purposes · Flags foreign_private_issuer
Veraxa Biotech Holding AG filed an amended F-1/A registration statement to include exhibits related to its Business Combination and recent financings. The filing highlights the company's transition from a private entity to a public company through a merger, along with multiple securities offerings, including a $27.5 million senior secured note, a $50 million private placement with Lincoln Park, and share lending agreements. The company remains an emerging growth entity with ongoing clinical development risks.
2026-08-05 · 0001829126-26-008400
F-1/A
amended
Amended foreign registration statement
Updated foreign registration statement filed after SEC comments or deal changes.
First tracked pre-IPO filing for this issuer.
Ordinary Shares · Warrants to purchase shares at $11.50 per share · Use of proceeds For general corporate purposes and business combination-related expenses · Flags warrants
Veraxa Biotech Holding AG filed an amended F-1/A registration statement for its upcoming IPO, detailing updates to its business combination, recent private placements, and share lending agreements. The filing confirms the completion of the Business Combination on June 10, 2026, and includes new financings such as the High Trail Financing ($27.5M senior note and warrants), a $50M Lincoln Park purchase agreement, and a Cantor Fitzgerald fee modification. The company also outlines recent private offerings, including share issuances to directors, investors, and entities like Xlife Sciences AG under a share lending agreement. The filing emphasizes compliance with Swiss law while addressing SEC requirements for indemnification and registration exemptions.
2026-08-05 · 0001829126-26-008399
F-1
filed
Initial foreign registration statement
Initial public filing for a foreign issuer submitted to start the SEC review process.
Follows F-1 in the pre-IPO sequence.
Veraxa Biotech Holding AG's F-1 filing highlights significant risks associated with its clinical development pipeline, including the high likelihood of product candidate discontinuation due to efficacy, safety, or resource prioritization issues. The company emphasizes the uncertainty of clinical trial outcomes, regulatory approvals, and commercialization, noting that none of its current candidates may become marketable. Key risks include delays in patient enrollment, adverse side effects, and the unpredictability of trial results across stages. The filing also underscores challenges in managing toxicities with third-party CROs and the impact of combination therapies on safety profiles.
2026-07-31 · 0001829126-26-008247
F-1
filed
Initial foreign registration statement
Initial public filing for a foreign issuer submitted to start the SEC review process.
Follows 20-F in the pre-IPO sequence.
Veraxa Biotech Holding AG's current F-1 filing highlights significant risks associated with its clinical development pipeline, including the high likelihood of product candidate discontinuation due to efficacy, safety, or strategic reasons. The company emphasizes uncertainties in clinical trial outcomes, regulatory approvals, and commercialization, noting that none of its current candidates may become marketable. Key risks include delays in trials, adverse events, challenges in patient enrollment, and the potential for late-stage trial failures despite earlier positive results. The filing underscores the volatile nature of biotechnology development and its impact on business prospects.
2026-07-31 · 0001829126-26-008246
20-F
supplemental
20-F
Pre-IPO filing captured from the SEC submission timeline.
Follows CERT in the pre-IPO sequence.
2026-06-16 · 0001829126-26-006546
CERT
inactive
CERT
Pre-IPO filing captured from the SEC submission timeline.
Follows 8-A12B in the pre-IPO sequence.
2026-06-10 · 0001354457-26-000557
8-A12B
effective
Exchange Act registration
Registration filed to list the securities under the Exchange Act ahead of trading.
Follows 424B3 and registers the class of securities for exchange listing.
2026-06-09 · 0001829126-26-006236
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
Class A and Class B · SPAC Units separated into Class A Ordinary Shares and Warrants · SPAC Warrants converted into PubCo Warrants · Use of proceeds Business combination and related transactions · Flags cayman_holding_company, dual_class
Veraxa Biotech Holding AG's current 424B3 filing highlights significant risks associated with its clinical development pipeline. The company emphasizes that its product candidates face high uncertainty in clinical trials, including potential discontinuation due to lack of efficacy, safety concerns, or resource prioritization. Key risks include delays in trial completion, adverse events, challenges in patient enrollment, and regulatory hurdles. The filing underscores that none of its current product candidates may achieve commercial success, with potential material adverse impacts on business and financial outcomes.
2026-02-19 · 0001829126-26-001490
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows F-4/A and marks the registration effective.
2026-02-17 · 9999999995-26-000595
F-4/A
amended
F-4/A
Pre-IPO filing captured from the SEC submission timeline.
Updates the prior F-4/A filing.
Flags cayman_holding_company
2026-02-13 · 0001829126-26-001295
F-4/A
amended
F-4/A
Pre-IPO filing captured from the SEC submission timeline.
Updates the prior F-4/A filing.
Flags cayman_holding_company, foreign_private_issuer
2026-02-03 · 0001829126-26-000902
F-4/A
amended
F-4/A
Pre-IPO filing captured from the SEC submission timeline.
Updates the prior 425 filing.
SPAC Class A Ordinary Share · Each SPAC Unit includes one Class A Ordinary Share and one-half of a Warrant · Warrants exercisable for Class A Ordinary Shares at $11.50 per share · Use of proceeds Proceeds to be used for general corporate purposes · Flags cayman_holding_company, units
2025-11-28 · 0001829126-25-009492
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows F-4/A in the pre-IPO sequence.
2025-09-30 · 0001829126-25-007783
F-4/A
amended
F-4/A
Pre-IPO filing captured from the SEC submission timeline.
Updates the prior F-4/A filing.
SPAC Class A Ordinary Share · Flags cayman_holding_company, foreign_private_issuer · Underwriters self-underwritten
2025-09-29 · 0001829126-25-007725
F-4/A
amended
F-4/A
Pre-IPO filing captured from the SEC submission timeline.
Updates the prior F-4 filing.
SPAC Class A Ordinary Share · Use of proceeds for the business combination and related transactions · Flags cayman_holding_company, units
2025-07-31 · 0001829126-25-005637
F-4
filed
F-4
Pre-IPO filing captured from the SEC submission timeline.
First tracked pre-IPO filing for this issuer.
SPAC Class A Ordinary Share · Flags cayman_holding_company
2025-07-31 · 0001829126-25-005620
Comparable Deals
20 comparable deals
Healthcare & BiotechLast 18 months
Only 0 strict matches; expanded to 20 using nearest neighbors.
Showing top 8 by similarity.
Vogenx, Inc.
VOGX
same SICrecent IPO
BlossomHill Therapeutics, Inc.
BLSM
same SICrecent IPO
Latigo Biotherapeutics, Inc.
LTGO
same SICrecent IPO
Braveheart Bio, Inc.
BRVE
same SICrecent IPO
Apnimed, Inc.
APMD
same SICrecent IPO
Kardigan, Inc.
KARD
same SICrecent IPO
Parabilis Medicines, Inc.
PBLS
same SICrecent IPO
Seaport Therapeutics, Inc.
SPTX
same SICrecent IPO
Recent News
No recent news stored for this issuer.